The FDA has approved Bayer HealthCare’s Gadavist (gadobutrol) as the first intravenous MR contrast agent for evaluation of breast cancer in the U.S.

The role screening mammography should play has been debated for years—a debate that reached fever pitch following the shift in U.S. Preventive Services Task Force (USPSTF) guidelines in 2009—and the first half of 2014 has been no different.

Following the herd may lead you to make less moral decisions, as people exhibit less activity in the medial prefrontal cortex, the part of the brain tasked with reflection and morality, when they become part of a team.

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body’s head and neck region.

The Interactive Patient Profiler for AdreView is a simulation tool designed to help educate physicians on the use of AdreView (Iobenguane I 123 Injection) to assess mortality risk in patients with heart failure. The tool demonstrates the types of patients where the use of AdreView can provide further information to assist physicians in identifying patients who may have a lower one- and two-year mortality risk, among groups of patients with similar profiles based on other clinical information.

As the 2014 Annual Meeting for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) came to a close this year, Molecular Imaging sat down with Barry A. Siegel, MD, professor of radiology and medicine and chief of the nuclear medicine division at Washington University School of Medicine here in St. Louis. Siegel was honored this year with the most prestigious award presented during the meeting: the Benedict Cassen Prize.

General discontent followed a one-time, exponential price hike from Jubilant DraxImage starting April 1 for the company’s exclusive MAA kit for the preparation of technetium-99m albumin, a lung perfusion agent. An industry forum on challenges in the radiopharmaceutical realm presented during the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014 Annual Meeting in St. Louis featured a panel of speakers, including vice president of sales, marketing and business development for JDI, Kevin Brooks, who made a case for the company.

Piramal Imaging released details from research presented at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), currently underway at St. Louis Convention Center in St. Louis, Mo.